LN Pharma Consulting SRL
LN Pharma Consulting reported total assets of 94,232 € at the end of the 2025 financial year (annual accounts filed with the NBB on 27 Aug 2026).
The score of LN Pharma Consulting shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -39 % Total assets +373 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
LN Pharma Consulting's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 27 Aug 2026
- Year ended 31 Dec 2024filed on 18 Nov 2025
- Year ended 31 Dec 2023filed on 28 Jun 2024
- Year ended 31 Dec 2022filed on 30 Jun 2023
- Year ended 31 Dec 2021filed on 29 Jul 2022
LN Pharma Consulting's financial analysis
- Solvency12.2%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of LN Pharma Consulting
LN Pharma Consulting's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0751.561.740
- VAT number
- BE0751561740
- Peppol
- Registered · 0208:0751561740 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 28 Jul 2020
- Registered office
- 4101 Seraing
- Latest accounts
- 2025 · filed on 27 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
LN Pharma Consulting (SRL) has been based in Seraing since 2020, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 52,325 € and equity of 11,501 €; its revenue is not published. Its solvency stands at 12.2%, below the median of its sector (41.5%).
Companies similar to LN Pharma Consulting
Companies in the same business, of comparable size and area, outside its group.
- Belem Consulting Business and other management consultancy activities Liège · balance sheet 45,666 €
- OVUM Bxl Public relations and communication activities Uccle · balance sheet 776,837 €
- Farmacyze Retail sale of pharmaceutical products Ostend · balance sheet 73,863 €
- Pharm'Training Lab Retail sale of pharmaceutical products Leuze-en-Hainaut · balance sheet 87,540 €
- Temapharm Retail sale of pharmaceutical products Neupré · balance sheet 191,548 €
- Tupharma Connect AND Trade Retail sale of pharmaceutical products Ghent · balance sheet 95,322 €
- Neopharm Retail sale of pharmaceutical products Jette · balance sheet 94,350 €
- IBCM Pharma Retail sale of pharmaceutical products Lasne · balance sheet 100,830 €
Frequently asked questions about LN Pharma Consulting
What is the revenue of LN Pharma Consulting?
LN Pharma Consulting files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of LN Pharma Consulting?
In Belgium, the VAT number is the company number prefixed with BE: BE0751561740 for LN Pharma Consulting, if the company is VAT-registered. Its company number (CBE) is 0751.561.740.
Where is the registered office of LN Pharma Consulting?
According to the CBE register, the registered office of LN Pharma Consulting is in 4101 Seraing.
What is the equity of LN Pharma Consulting?
At the close of the 2025 financial year, the equity of LN Pharma Consulting amounts to 11,501 €, a solvency of 12.2% of total assets.
Who manages LN Pharma Consulting?
The register lists 1 active mandates at LN Pharma Consulting. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of LN Pharma Consulting
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →